<Table 3>
 <caption text="

         Treatment guidelines incorporating DL
         
          CO
         
         or splenomegaly reduction as clinically significant outcomes.
        
">
 </caption>
 <row row="0">
  <cell col="0" row="0" text="
           Disease
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="0" text="
           Outcome
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="0" text="
           Guideline
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="0" text="
           Reference
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="1">
  <cell col="0" row="1" text="
           Gaucher disease
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="1" text="
           Splenomegaly
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="1" text="



              •
             

              Spleen volume should be expressed as multiples of normal with a treatment goal of 2–8 times reduction of normal and assessments at different time points up to 5 years
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="1" text="



              •
             

              European Working Group on Gaucher Disease [
              
               31
              
              ,
              
               32
              
              ]
             



              •
             

              US Food and Drug Administration [
              
               29
              
              ]
             



              •
             

              European Medical Association [
              
               30
              
              ]
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="2">
  <cell col="0" row="2" text="
           Myelofibrosis
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="2" text="
           Splenomegaly
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="2" text="



              •
             

              Reduction of ≥35% in spleen volume as assessed by MRI or CT is indicative of response to treatment
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="2" text="



              •
             

              WHO International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet consensus report [
              
               35
              
              ]
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="3">
  <cell col="0" row="3" text="
           Idiopathic pulmonary fibrosis
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="3" text="
           DL
           
            CO
           
">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="3" text="



              •
             

              A decrease of &gt;15% DL
              
               CO
              
              in absolute values is associated with disease worsening/increased risk of mortality
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="3" text="



              •
             

              2017 Spanish IPF guidelines [
              
               58
              
              ,
              
               59
              
              ]
             



              •
             

              2017 French IPF guidelines [
              
               60
              
              ]
             


">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
  </cell>
 </row>
 <statements>
  <statement id="0" text="The outcome is DL CO when the reference is • 2017 Spanish IPF guidelines [ , ] • 2017 French IPF guidelines [ ]" type="">
  </statement>
  <statement id="1" text="The value of • Reduction of ≥35% in spleen volume as assessed by MRI or CT is indicative of response to treatment for guideline corresponds to the value of • WHO International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet consensus report [ ] for reference" type="">
  </statement>
  <statement id="2" text="The reference is • 2017 Spanish IPF guidelines [ , ] • 2017 French IPF guidelines [ ] when the guideline is • A decrease of &gt;15% DL CO in absolute values is associated with disease worsening/increased risk of mortality" type="">
  </statement>
  <statement id="3" text="The reference is • European Working Group on Gaucher Disease [ , ] • US Food and Drug Administration [ ] • European Medical Association [ ] when the guideline is • Spleen volume should be expressed as multiples of normal with a treatment goal of 2–8 times reduction of normal and assessments at different time points up to 5 years" type="">
  </statement>
  <statement id="4" text="The value of DL CO for outcome corresponds to the value of • A decrease of &gt;15% DL CO in absolute values is associated with disease worsening/increased risk of mortality for guideline" type="">
  </statement>
  <statement id="5" text="The reference is • 2017 Spanish IPF guidelines [ , ] • 2017 French IPF guidelines [ ] when the guideline is • Reduction of ≥35% in spleen volume as assessed by MRI or CT is indicative of response to treatment" type="">
  </statement>
  <statement id="6" text="The value of • WHO International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet consensus report [ ] for reference corresponds to the value of • A decrease of &gt;15% DL CO in absolute values is associated with disease worsening/increased risk of mortality for guideline" type="">
  </statement>
  <statement id="7" text="The value of DL CO for outcome corresponds to the value of • Reduction of ≥35% in spleen volume as assessed by MRI or CT is indicative of response to treatment for guideline" type="">
  </statement>
  <statement id="8" text="The value of • WHO International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet consensus report [ ] for reference corresponds to the value of DL CO for outcome" type="">
  </statement>
  <statement id="9" text="The reference is • European Working Group on Gaucher Disease [ , ] • US Food and Drug Administration [ ] • European Medical Association [ ] when the guideline is • Reduction of ≥35% in spleen volume as assessed by MRI or CT is indicative of response to treatment" type="">
  </statement>
  <statement id="10" text="The value • WHO International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet consensus report [ ] belongs to reference" type="">
  </statement>
  <statement id="11" text="The value DL CO belongs to outcome" type="">
  </statement>
  <statement id="12" text="• A decrease of &gt;15% DL CO in absolute values is associated with disease worsening/increased risk of mortality is in guideline" type="">
  </statement>
  <statement id="13" text="• Reduction of ≥35% in spleen volume as assessed by MRI or CT is indicative of response to treatment is in guideline" type="">
  </statement>
  <statement id="14" text="The value • European Working Group on Gaucher Disease [ , ] • US Food and Drug Administration [ ] • European Medical Association [ ] belongs to reference" type="">
  </statement>
  <statement id="15" text="• Spleen volume should be expressed as multiples of normal with a treatment goal of 2–8 times reduction of normal and assessments at different time points up to 5 years is in guideline" type="">
  </statement>
  <statement id="16" text="• 2017 Spanish IPF guidelines [ , ] • 2017 French IPF guidelines [ ] is in reference" type="">
  </statement>
  <statement id="17" text="• Spleen volume should be expressed as multiples of normal with a treatment goal of 2–8 times reduction of normal and assessments at different time points up to 5 years is in reference" type="">
  </statement>
  <statement id="18" text="The value • 2017 Spanish IPF guidelines [ , ] • 2017 French IPF guidelines [ ] belongs to outcome" type="">
  </statement>
  <statement id="19" text="The value • European Working Group on Gaucher Disease [ , ] • US Food and Drug Administration [ ] • European Medical Association [ ] belongs to guideline" type="">
  </statement>
  <statement id="20" text="The value Splenomegaly belongs to reference" type="">
  </statement>
  <statement id="21" text="The value DL CO belongs to guideline" type="">
  </statement>
  <statement id="22" text="The value • Reduction of ≥35% in spleen volume as assessed by MRI or CT is indicative of response to treatment belongs to reference" type="">
  </statement>
  <statement id="23" text="The value • WHO International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet consensus report [ ] belongs to outcome" type="">
  </statement>
  <statement id="24" text="All the values in guideline are distinct." type="">
  </statement>
  <statement id="25" text="Reference has no duplicate values." type="">
  </statement>
  <statement id="26" text="Outcome always has the same value." type="">
  </statement>
  <statement id="27" text="Outcome has no duplicate values." type="">
  </statement>
 </statements>
</Table 3>
<Table 2>
 <caption text="

         ASMD observational and natural history studies of patients with chronic ASMD describing associations of DL
         
          CO
         
         or splenomegaly with morbidity, mortality or quality of life.
        
">
 </caption>
 <row row="0">
  <cell col="0" row="0" text="
           Study design
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="0" text="
           Relevant population
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="0" text="
           DL
           
            CO
           
           -related
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="0" text="
           Spleen-related
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="4" row="0" text="
           Reference
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="1">
  <cell col="0" row="1" text="
           Multicenter, multinational prospective, cross-sectional natural history study (US, Italy, Brazil, France and Germany)
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="1" text="
           59 pediatric or adult patients with chronic ASMD ranging in age from 7 to 65 years
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="1" text="
           Shortness of breath; disease severity
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="1" text="
           Bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted DLco, % predicted FVC)
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="4" row="1" text="
           McGovern et al. [
           
            23
           
           ]
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="2">
  <cell col="0" row="2" text="
           Retrospective and prospective natural history study (Belgium and the Netherlands)
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="2" text="
           25 pediatric or adult patients with chronic ASMD with up to 11 years of follow-up
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="2" text="
           6 min walk test; disease progression
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="2" text="
           No significant correlations between baseline spleen volume and platelets, lipids, DLco, bone marrow fat burden, chitotriosidase
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="4" row="2" text="
           Hollack et al. [
           
            15
           
           ]
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="3">
  <cell col="0" row="3" text="
           Systematic evaluation of morbidity and mortality (US single center)
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="3" text="
           103 pediatric or adult patients with chronic ASMD ranging in age from 1 to 72 years
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="3" text="
           NR
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="3" text="
           Higher mortality in splenectomized patients
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="4" row="3" text="
           McGovern et al. [
           
            14
           
           ]
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="4">
  <cell col="0" row="4" text="
           Assessment of bone scans (US single center)
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="4" text="
           46 pediatric or adult patients with chronic ASMD ranging in age from 1.6 to 54.5 years
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="4" text="
           NR
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="4" text="
           Lumbar bone mineral density
           
            Z
           
           -score
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="4" row="4" text="
           Wasserstein et al. [
           
            25
           
           ]
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
 </row>
 <row row="5">
  <cell col="0" row="5" text="
           Cross-sectional anlysis of growth in children (US single center)
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="1" row="5" text="
           23 children and adolescents with chronic ASMD ranging in age from 3.7 to 18.3 years
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="2" row="5" text="
           NR
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="3" row="5" text="
           Short stature and low weight
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
  <cell col="4" row="5" text="
           Wasserstein et al. [
           
            24
           
           ]
          ">
   <evidence statement_id="0" type="" version="">
   </evidence>
   <evidence statement_id="1" type="" version="">
   </evidence>
   <evidence statement_id="2" type="" version="">
   </evidence>
   <evidence statement_id="3" type="" version="">
   </evidence>
   <evidence statement_id="4" type="" version="">
   </evidence>
   <evidence statement_id="5" type="" version="">
   </evidence>
   <evidence statement_id="6" type="" version="">
   </evidence>
   <evidence statement_id="7" type="" version="">
   </evidence>
   <evidence statement_id="8" type="" version="">
   </evidence>
   <evidence statement_id="9" type="" version="">
   </evidence>
   <evidence statement_id="10" type="" version="">
   </evidence>
   <evidence statement_id="11" type="" version="">
   </evidence>
   <evidence statement_id="12" type="" version="">
   </evidence>
   <evidence statement_id="13" type="" version="">
   </evidence>
   <evidence statement_id="14" type="" version="">
   </evidence>
   <evidence statement_id="15" type="" version="">
   </evidence>
   <evidence statement_id="16" type="" version="">
   </evidence>
   <evidence statement_id="17" type="" version="">
   </evidence>
   <evidence statement_id="18" type="" version="">
   </evidence>
   <evidence statement_id="19" type="" version="">
   </evidence>
   <evidence statement_id="20" type="" version="">
   </evidence>
   <evidence statement_id="21" type="" version="">
   </evidence>
   <evidence statement_id="22" type="" version="">
   </evidence>
   <evidence statement_id="23" type="" version="">
   </evidence>
   <evidence statement_id="24" type="" version="">
   </evidence>
   <evidence statement_id="25" type="" version="">
   </evidence>
   <evidence statement_id="26" type="" version="">
   </evidence>
  </cell>
 </row>
 <statements>
  <statement id="0" text="The spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Short stature and low weight when the relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years is 23 children and adolescents with chronic ASMD ranging in age from 3.7 to 18.3 years" type="">
  </statement>
  <statement id="1" text="The spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Higher mortality in splenectomized patients when the hollack et al. [ ] in mcgovern et al. [ ] in reference is McGovern et al. [ ]" type="">
  </statement>
  <statement id="2" text="The value of McGovern et al. [ ] for hollack et al. [ ] in mcgovern et al. [ ] in reference corresponds to the value of 103 pediatric or adult patients with chronic ASMD ranging in age from 1 to 72 years for relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years" type="">
  </statement>
  <statement id="3" text="The spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Lumbar bone mineral density Z -score when the relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years is 46 pediatric or adult patients with chronic ASMD ranging in age from 1.6 to 54.5 years" type="">
  </statement>
  <statement id="4" text="The relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years is 103 pediatric or adult patients with chronic ASMD ranging in age from 1 to 72 years when the spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Higher mortality in splenectomized patients" type="">
  </statement>
  <statement id="5" text="The spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Lumbar bone mineral density Z -score when the relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years is 103 pediatric or adult patients with chronic ASMD ranging in age from 1 to 72 years" type="">
  </statement>
  <statement id="6" text="The spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Higher mortality in splenectomized patients when the relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years is 23 children and adolescents with chronic ASMD ranging in age from 3.7 to 18.3 years" type="">
  </statement>
  <statement id="7" text="The spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Lumbar bone mineral density Z -score when the hollack et al. [ ] in mcgovern et al. [ ] in reference is McGovern et al. [ ]" type="">
  </statement>
  <statement id="8" text="The value of Higher mortality in splenectomized patients for spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase corresponds to the value of 46 pediatric or adult patients with chronic ASMD ranging in age from 1.6 to 54.5 years for relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years" type="">
  </statement>
  <statement id="9" text="The spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase is Lumbar bone mineral density Z -score when the relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years is 23 children and adolescents with chronic ASMD ranging in age from 3.7 to 18.3 years" type="">
  </statement>
  <statement id="10" text="The value 46 pediatric or adult patients with chronic ASMD ranging in age from 1.6 to 54.5 years belongs to relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years" type="">
  </statement>
  <statement id="11" text="McGovern et al. [ ] is in hollack et al. [ ] in mcgovern et al. [ ] in reference" type="">
  </statement>
  <statement id="12" text="23 children and adolescents with chronic ASMD ranging in age from 3.7 to 18.3 years is in relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years" type="">
  </statement>
  <statement id="13" text="The value Short stature and low weight belongs to spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase" type="">
  </statement>
  <statement id="14" text="Higher mortality in splenectomized patients is in spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase" type="">
  </statement>
  <statement id="15" text="Lumbar bone mineral density Z -score is in spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase" type="">
  </statement>
  <statement id="16" text="The value 103 pediatric or adult patients with chronic ASMD ranging in age from 1 to 72 years belongs to relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years" type="">
  </statement>
  <statement id="17" text="The value 46 pediatric or adult patients with chronic ASMD ranging in age from 1.6 to 54.5 years belongs to hollack et al. [ ] in mcgovern et al. [ ] in reference" type="">
  </statement>
  <statement id="18" text="The value Lumbar bone mineral density Z -score belongs to relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years" type="">
  </statement>
  <statement id="19" text="Lumbar bone mineral density Z -score is in hollack et al. [ ] in mcgovern et al. [ ] in reference" type="">
  </statement>
  <statement id="20" text="The value 46 pediatric or adult patients with chronic ASMD ranging in age from 1.6 to 54.5 years belongs to 6 min walk test; disease progression in shortness of breath; disease severity in dl co -related" type="">
  </statement>
  <statement id="21" text="The value 103 pediatric or adult patients with chronic ASMD ranging in age from 1 to 72 years belongs to hollack et al. [ ] in mcgovern et al. [ ] in reference" type="">
  </statement>
  <statement id="22" text="McGovern et al. [ ] is in 6 min walk test; disease progression in shortness of breath; disease severity in dl co -related" type="">
  </statement>
  <statement id="23" text="The value Higher mortality in splenectomized patients belongs to relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years" type="">
  </statement>
  <statement id="24" text="All the values in spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase are distinct." type="">
  </statement>
  <statement id="25" text="6 min walk test; disease progression in shortness of breath; disease severity in dl co -related always has the same value." type="">
  </statement>
  <statement id="26" text="Relevant population in 25 pediatric or adult patients with chronic asmd with up to 11 years of follow-up in 59 pediatric or adult patients with chronic asmd ranging in age from 7 to 65 years has no duplicate values." type="">
  </statement>
  <statement id="27" text="Hollack et al. [ ] in mcgovern et al. [ ] in reference always has the same value." type="">
  </statement>
  <statement id="28" text="6 min walk test; disease progression in shortness of breath; disease severity in dl co -related has no duplicate values." type="">
  </statement>
  <statement id="29" text="Spleen-related,bleeding/bruising, increased liver volume, atherogenic lipid profile, below average height z scores, hematologic abnormalites, lung parameters (including fibrosis scores, % predicted dlco, % predicted fvc),no significant correlations between baseline spleen volume and platelets, lipids, dlco, bone martr fat burden, chitotriosidase always has the same value." type="">
  </statement>
 </statements>
</Table 2>
